Spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's disease
申请人:Coburn A. Craig
公开号:US20070021454A1
公开(公告)日:2007-01-25
The present invention is directed to spiropiperidine compounds of formula (I)
and tautomers thereof, which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved.
Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
申请人:Merck, Sharp & Dohme Corp.
公开号:US08211904B2
公开(公告)日:2012-07-03
The present invention is directed to spiropiperidine compounds of formula (I)
and tautomers thereof, which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved.
作者:Jennifer L Matthews、Duncan R McArthur、Kenneth W Muir
DOI:10.1016/s0040-4039(02)01085-7
日期:2002.7
stereoselective synthesis of unnatural cyclic sila-substituted β-aminoacids has been developed from simple starting materials. The key step is nucleophilic ring opening of an intermediate aziridine with an umpolung synthon for the carboxylate anion. Functional group manipulation and deprotection reactions allow access to the desired trans β-aminoacids.